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The aryl hydrocarbon receptor (AhR) and glucocorticoid
receptor (GR) are ligand-activated transcription factors and
members of the basic helix–loop–helix Period-aryl hydrocarbon
nuclear translocator-single minded and nuclear hormone receptor
superfamilies, respectively. Besides their individual role as acti-
vators of specific gene transcription, also interplay between both
transcription factors can be an important mechanism of regula-
tion. In this study, we report that GR can strongly activate AhR-
mediated transcription and consequent gene expression in rat
H4IIe cells. Reporter gene assays showed an enhanced effect of
dexamethasone on the dioxin response mediated by GR in rat
H4IIe cells and mouse Hepa 1c1c7 cells, but not in human HepG2
cells and human T47D cells. These deviations between the rodent
and human cell lines were confirmed by CYP1A1 enzyme
activities. In addition, quantitative reverse transcription–PCR
showed enhanced GR-mediated effects of dexamethasone on
endogenous 2,3,7,8-tetrachlorodibenzo-[p]-dioxin target genes as
well in rat H4IIe cells, but not in human HepG2 and human T47D
cells. Surprisingly, AhR itself was upregulated by combined
dioxin/glucocorticoid exposure in rat H4IIe cells but not in the
human cells which could be explained by the presence of two
putative glucocorticoid response elements in the rat AhR pro-
moter, but not in the human AhR promoter. This GR-mediated
expression of dioxin target genes through upregulation of the AhR
in rat but not in human cells opens the possibility that dioxin
responses in rodent-based models for toxicity differ from humans
and provides new insight into the interactions of stress-related
pathways, biological effects of dioxin-like compounds and may
possibly have implications for risk assessment.
Key Words: aryl hydrocarbon receptor; CALUX; dioxin;
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Polyhalogenated aromatic hydrocarbons (PHAHs) including
dioxins and dioxin-like polychlorinated biphenyls (PCBs)
induce a wide variety of effects in mammals, birds, and fish
such as immunotoxicity, carcinogenicity, and metabolic
changes. These compounds bind to an intracellular receptor,
known as the aryl hydrocarbon receptor (AhR). AhR is
a member of the basic helix–loop–helix Period-ARNT (aryl
hydrocarbon nuclear translocator)–single minded family of
transcription factors that control a variety of developmental and
physiological events, including neurogenesis, toxin meta-
bolism, circadian rhythms, hypoxia response, and steroid
hormone receptor function (Gu et al., 2000). Ligand binding
to the AhR is presumed to produce conformational changes in
the AhR protein followed by translocation of the PHAH–AhR
complex from the cytoplasm into the nucleus of the cell
(Pollenz et al., 1994) and dimerization with its nuclear partner
ARNT (Safe, 1995). The AhR–ARNT heterodimer forms an
active transcription factor which binds with high affinity to
defined DNA sequences called xenobiotic responsive elements
(XREs) (Denison et al., 1988). Binding of the AhR–ARNT
dimer to the XRE triggers the transcription of XRE-associated
genes, such as the drug metabolizing monooxygenases cyto-
chrome P4501A1 (CYP1A1), CYP1A2, and CYP1B1 (enzymes
participating in biotransformation phase I) (Hankinson, 1995)
as well as phase II enzymes like glutathione-S-transferase (GST)
and nicotinamide adenine dinucleotide phosphate, reduced
(NADPH) quinone oxireductase (Rushmore and Kong, 2002).
Although its physiological role is unknown, the AhR mediates
most, if not all, of the toxic effects of 2,3,7,8-tetrachlorodibenzo-
[p]-dioxin (TCDD) (Lahvis and Bradfield, 1998).
Glucocorticoids are steroid hormones which are important
regulators of gluconeogenesis, cellular proliferation and dif-
ferentiation, and inhibition of inflammation. The effects of
glucocorticoids in target cells are mediated by the glucocor-
ticoid receptor (GR), a member of the nuclear hormone
receptor superfamily including receptors for steroids, retinoids,
and thyroid hormones (McKenna and O’ Malley, 2002). GR is
a ligand-dependent transcription factor which acts as a homo-
dimer that regulates specific gene expression by binding to
specific glucocorticoid response elements (GREs) within the
regulatory DNA sequences of many glucocorticoid-responsive
genes, referred to as type 1 mechanism of GR action (Bamberger
et al., 1996). Besides direct transcriptional regulation of
specific target genes by GR, also protein–protein interactions
with transcription factors of distinct families (in the absence of
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specific DNA binding; type 2 mechanism of GR action) have
been described such as activating protein-1, nuclear factor jB
(NF-jB), estrogen receptor (ER), and thyroid hormone receptor
(Bamberger et al., 1996). Usually, this type 2 GR action results
in inhibition rather than activation of target genes and is espe-
cially relevant for the tissue specific anti-inflammatory and immu-
nosuppressive effects of glucocorticoids (Dumont et al., 1998).
Besides the effect of AhR as an activator of gene transcription,
crosstalk has been observed among AhR and other nuclear
receptors, which has been most well studied with respect to ER
signaling (Matthews and Gustafsson, 2006). Activated AhR
inhibits ER activity through a number of different mechanisms
(Harper et al., 1994; Kharat and Saatcioglu, 1996; Rogers and
Denison, 2002), whereas ERa has been reported to have
a positive role in AhR signaling (Ohtake et al., 2003). In ad-
dition, the progesterone receptor negatively interferes with
AhR-mediated transcription (Kuil et al., 1998), while mutual inter-
ference between the AhR and the androgen receptor (Jana et al.,
1999), but also between the AhR and NF-jB has been reported
(Tjian et al., 1999). Crosstalk between glucocorticoids and the
dioxin pathway also exists, reported as dexamethasone-mediated
potentiation of CYP1A1 induction and 7-ethoxyresorufine-
O-deethylase (EROD) activities in rat hepatoma H4IIe cells
(Lai et al., 2004; Wiebel and Cikryt, 1990), fetal rat hepatocytes
(Mathis et al., 1989; Sherratt et al., 1990), adult rat hepatocytes
(Pinaire et al., 2004; Xiao et al., 1995), and interaction between
TCDD and glucocorticoids in embryonic palate (Abott, 1995)
and livers of adrenalectomized- or neonatal rat models (Linder
et al., 1999). So far, the mechanism behind this crosstalk
between dioxins and glucocorticoids is very unclear.
Recently, it was shown that glucocorticoids have a positive
response in the dioxin-responsive Chemically Activated LUcif-
erase eXpression (DR CALUX) bioassay, and were able to
enhance the response obtained with TCDD (Hoogenboom et al.,
1999). The goal of this study is to determine to what extent
glucocorticoids interfere with dioxin signaling and what the
mechanism(s) of glucocorticoid-enhanced dioxin signaling is.
Furthermore, large differences in TCDD susceptibility within
and between species exist (Hengstler et al., 1999; Karchner
et al., 2006; Poland et al., 1994) believed to be partly due to
ligand affinity differences between polymorphic AhRs. There-
fore, we have studied in detail how rodent and human cell lines
deviate in their responses to TCDD and how the interaction of
glucocorticoids influences these. This may provide additional
insight in the known interactions of stress-related pathways and
biological effects of dioxin-like compounds and the known inter-
and intraspecies differences in dioxin signaling.
MATERIALS AND METHODS
Chemicals. Dexamethasone (dex), cortisol, cycloheximide, and mifepris-
tone (Ru486) were obtained from Sigma-Aldrich (Zwijndrecht, The
Netherlands). TCDD was purchased from Cambridge Isotope Laboratories
(Andover, MA). All chemicals were diluted in either ethanol or dimethylsulf-
oxide (DMSO; Acros, Geel, Belgium) and stored at 20C, except for TCDD
which was stored at room temperature. Neomycin (G418) was purchased from
Life Technologies (Breda, The Netherlands).
DNA constructs. Full-length complementary DNA (cDNA) for human GR
(ATCC, Manassas, VA) was inserted in the multiple cloning site (MCS) of the
expression vector pSG5-neo to obtain pSG5-neo-GR (Sonneveld et al., 2005).
The Gudluc1.1 dioxin reporter gene construct has been described elsewhere
(Garrison et al., 1996). The dioxin reporter gene pDREtataLuc was constructed
as follows: four tandem repeats of a DRE (dioxin-responsive element) oligo
(based on the  985 to  979 DRE sequence of the rat CYP1A1 promoter)
upstream of the minimal adenovirus E1B TATA promoter sequence were
inserted in the MCS of the enhanced luciferase reporter gene construct pGL3-
basic. The glucocorticoid reporter construct pMMTVluc was described earlier
(Sonneveld et al., 2005).
Cell culture. Human T47D breast cancer cells, human HepG2 cells, mouse
Hepa1 1c1c7 cells, and rat H4IIe cells (all obtained from ATCC) were cultured
in a 1:1 mixture of Dulbecco’s modified Eagle’s medium and Ham’s F12
medium (DF, Gibco) supplemented with 7.5% fetal calf serum (FCS). DR
CALUX cells were cultured in DF medium supplemented with 7.5% FCS and
200 lg/ml G418.
Transient transfections. For transient transfections, cells were plated in
24-well cell culture plates. After culturing for one day, cells were transfected
with 1 lg reporter plasmid (pGudLuc 1.1 or pMMTVluc), 200 ng SV2-lacZ,
and 200 ng expression plasmid pSG5-neo-hGR or empty vector DNA (pSG5-
neo) using the calcium phosphate coprecipitation method. Luciferase activity
was corrected for transfection efficiency by measuring b-galactosidase activity
as a result of SV2-lacZ cotransfection.
Establishment of stable DR CALUX cell lines. Generation of the H4IIe-
pGudLuc cell line has previously been described (Garrison et al., 1996). Stable
H4IIe-pDREtataLuc cells were generated as follows: H4IIe cells were
transfected with pDREtataLuc and pSG5-neo using calcium phosphate
coprecipitation to generate DR CALUX cells. Neomycin-resistant clones were
tested for their response to TCDD and five clones showed consequent high
response. One of these responding to the lowest concentration of TCDD
(10pM) was selected for further investigation.
CALUX bioassays. DR CALUX cells (H4IIe-pGudLuc and H4IIe-
pDREtataLuc stable cell lines) were plated in 96-well cell culture plates with
phenol red-free DF medium supplemented with 5% dextran coated charcoal
stripped FCS (DCC-FCS; Sonneveld et al., 2005) at a volume of 200 ll per
well. The next day, the medium was refreshed and cells were incubated with the
compounds to be tested (dissolved in ethanol or DMSO) in triplicate at
a 1:1000 dilution. After 24 h the medium was removed, cells were lysed in 30
ll of Triton-lysis buffer and measured for luciferase activity using
a luminometer (Lucy2; Anthos Labtec Instruments, Wals, Austria) for 0.1
min per well.
EROD bioassay. The Micro-EROD bioassay was performed as described
earlier (Behnisch et al., 2002) with minor modifications. Briefly, cells were
seeded into 96-well cell culture plates with phenol red-free DF medium
supplemented with 5% DCC-FCS. The next day, the medium was refreshed
and cells were incubated with the compounds to be tested (dissolved in ethanol
or DMSO) in triplicate at a 1:1000 dilution. After 24 h the medium was
removed, cells were washed twice with 0.53 PBS and lysed in 30 ll of water.
Plates were frozen at  80C for minimally 20 min. After thawing, 50 ll of
dicumarol buffer (40lM dicumarol in Tris buffer pH 8; Sigma-Aldrich) and 25
ll of 7-ethoxyresorufin (20lM in dicumerol buffer; Sigma-Aldrich) were added
to the wells. After incubation at 37C for 20 min, 25 ll of NADPH (1mM in
dicumarol buffer) was added and mixed. Plates were incubated at 37C for 1 h
and resorufin-associated fluorescence was measured at 530-nm excitation and
590-nm emission using a fluorescence plate reader (Packard fluorocount, model
BF10001). Measured values were corrected for the protein content per well.
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Quantitative reverse transcription–PCR. Total RNA was isolated using
nucleospin RNAII columns (Macherey-Nagel, Du¨ren, Germany). cDNA was
prepared with the iScript cDNA synthesis kit (Bio-Rad, Veenendaal, The
Netherlands) from 1 lg of total RNA. Aliquots of 5-ll cDNAs (1:10 diluted)
were used as templates for real-time PCR using SYBR green (iQ supermix;
Bio-Rad, Veenendaal, The Netherlands) in the MyIQ single color real-time
PCR Detection System (Bio-Rad, Veenendaal, The Netherlands). Gene- and
species-specific primers were designed for AhR, CYP1A1, CYP1A2, CYP1B1,
NMOR, GST-A1, HFH1, SGK, FKBP51, luciferase (from the pGL2 vector),
and RBPO (36B4; internal control) using Beacon designer 4.01 (PREMIER
Biosoft International, Palo Alto, CA). Table 1 shows the sequences of the sense
and antisense primers, amplicon lengths, and accession numbers of the
analyzed genes. Threshold CT values for each cDNA were determined and
relative gene expression analysis was performed using the Livak method (Livak
and Schmittgen, 2001). First the CT of the target gene was normalized to that of
the reference gene (RBPO), for both the test sample and the calibrator sample
(DMSO treated): DCT(test) ¼ CT(target, test)  CT(ref, test) and DCT(calibrator) ¼
CT(target, calibrator)  CT(ref, calibrator). Second, the DCT of the test sample was
normalized to the DCT of the calibrator: DDCT ¼ DCT(test)  DCT(calibrator).
Finally, the normalized expression ratio (fold induction) was calculated
according to the following equation: fold induction ¼ 2DDCT .
Identification of GREs and XREs in orthologous Ahr genes. Ten
kilobases of the regions upstream of the first exons, and introns 1 and 2 of rat,
mouse, and human Ahr genes were downloaded from ensembl (http://
www.ensembl.org) GRE sequences can show significant deviation from the
canonical AGAACA-nnn-TGTTCT palindromic consensus, particularly in the
5# half site (Nelson et al., 1999). To find potential GREs that are conserved
between species we took a very liberal definition based on the anchoring
nucleotides at positions 2 and 5 of each half site that are present in most
characterized GREs, and selected candidate response elements based on
comparison to JASPAR (MA0113) and Transfac (M00192) GRE position
weight matrices. Putative GREs were compared between rat, mouse, and
human Ahr genomic sequences. XRE sequences were identified according to
the core consensus [g/t][c/t]GCGTG[c/a/t] (Swanson et al., 1995).
Data analysis. Luciferase activity per well was measured as relative light
units. Fold induction was calculated by dividing the mean value of light units
from exposed and nonexposed (solvent control) wells. Luciferase induction as
a percentage of maximal TCDD activity was calculated by setting the highest
fold induction of TCDD at 100%. Data are represented as mean values ± SEM
from at least three independent experiments with each experimental point
performed in triplicate. Dose–response curves were fitted using the sigmoidal
fit y ¼ a0 þ a1/(1 þ exp((x  a2)/a3)) in GraphPad Prism (version 4.00 for
Windows, GraphPad Software, San Diego, CA), which determines the fitting
coefficients by an iterative process minimizing the c2 merit function (least
squares criterion). The EC50 values were calculated by determining the
concentration by which 50% of maximum activity was reached using the
sigmoidal fit equation. The relative transactivation activity of each compound
tested was calculated as the ratio of maximal luciferase reporter gene induction
values of each compound and the maximal luciferase reporter gene induction
value of reference compound TCDD. The transactivation activity of TCDD was
arbitrarily set at 100.
RESULTS
Glucocorticoids Enhance the TCDD Response in Stable
DR CALUX Reporter Cell Lines
Glucocorticoid-mediated potentiation of CYP1A1 messen-
ger RNA (mRNA) induction (Lai et al., 2004) and CYP1A1
enzymatic activity (Lai et al., 2004; Wiebel and Cikryt, 1990)
TABLE 1
Primer Sequences
Accession no. Genea Length (bp) Sense primer Anti-sense primer
NM_012540 rCyp1A1 124 GCTTCACACTTATCGCTAATG GTTGGGTCTGAGGCTATGG
NM_012541 rCyp1A2 207 TGTCCCCTTCACCATCCC AGCATCACCTTCTCACTCAG
NM_012940 rCyp1B1 183 TGCCTGCCACTATTACAGACATC CGTATGGTAAGTTGGGTTGGTCAC
NM_013149 rAhr 179 AAACCAAAGACACGGGATAAACTC TCGGACTCTGAAACTTGCTTAGG
K00136 rGstYa 177 AGTTGCTGCTATGTCTGGGAAG GGCACTTGGTCAAACATCAAATTC
AF153193 rHfh1 152 CGAGTACCTCATGGGCAAG TGAGCATCCAGTAATTGTCC
J02608 rNmor 170 GTATGCCACCATGTATGACAAGGG AGACCTGGAAGCCACAGAAGC
NM_019232 rSgk 139 TGAGTATCTCGCTCCTGAGGTTC GTCATACATCTCGGCTGTGTTCC
NM_001012174 rFkbp5 208 GAGCAAGAAGGCAGTAGAAGG GGCTTCCAGAATCACAGAGAC
X15096 rRplp0 163 CCATCGCCCCGTGTGAGG GCTCCCACCTTGTCTCCAGTC
NM_000499 hCyp1A1 171 CTGGCACTGTCAAGGATG ATTACTGATGAGGGTGAAGG
NM_000761 hCyp1A2 169 TCAGGTGGTGGTGTCAGTGG AGGCAGGTAGCGAAGGATGG
NM_000104 hCyp1B1 193 AACCGCAACTTCAGCAAC CGAAGATGTCAGTGATAGTGG
NM_001621 hAhr 163 CCAACATCACCTACGCCAGTCG ACATCTTGTGGGAAAGGCAGCAG
NM_145740 hGstA1 174 ATCCTCCTTCTGCCCGTATGTC AAGTTCCACCAGATGAATGTCAGC
AF225950 hHfh1 150 AGTACCTCATGGGCAAGTTC TGAGCATCCAGTAGTTGTCC
J03934 hNmor 195 ACCCTGCGAACTTTCAGTATCC AAGCAAACTCTCCTATGAACACTC
NM_005627 hSgk 119 AGGAGAACATTGAACACAACAGC TCCCAGGCACCACCAGTC
U71321 hFkbp51 225 TTGAGAAAGTGCTGGAAGTAAACC CCATTGCTTGACTGTCTGTTCC
NM_001002 hRplp0 198 GGCAGCATCTACAACCCTGAAGTG AAGTGGGAAGGTGTAATCCGTCTC
Notes. Oligonucleotide primers (5#–3#) of genes used in this study including gene accession numbers and amplicon lengths (bp).
aAbbreviations: r, rat; h, human;Cyp1A1, cytochrome P4501A1;Cyp1A2, cytochrome P4501A2;Cyp1B1, cytochrome P4501B1;GstYa, glutathione-S-transferase
Ya; GstA1, glutathione S-transferase A1; Hfh1, winged helix/forkhead transcription factor-1; Nmor, NAD(P)H:menadione oxidoreductase; Fkbp5, FK506 binding
protein 5; Fkbp51, FK506 binding protein 51; Rplp0, acidic ribosomal phosphoprotein P0.
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in TCDD or BaP-treated rat H4IIe hepatoma cells has been
demonstrated. This phenomenon was also noticed by using the
DR CALUX reporter gene assay (rat H4IIe cells containing the
dioxin-responsive pGudLuc reporter construct), which besides
responding to dioxins and dioxin-like compounds, was
reported to respond to glucocorticoids (Hoogenboom et al.,
1999). To study the mechanism of glucocorticoid/dioxin
interaction in more detail, two DR CALUX cell lines were
used (Fig. 1): the original DR CALUX cell line stably
containing the pGudLuc construct (Fig. 1A), which besides the
DREs may contain additional responsive elements from the
CYP1A1 and/or MMTV-long terminal repeat (LTR) sequences
(e.g., for the GR pathway), and a second H4IIe cell line only
containing a minimal promoter construct with four multi-
merized DREs in front of the TATA promoter coupled to
luciferase (pDREtataLuc) (Fig. 1A). Such a minimal promoter
has the advantage that regulation through promoter elements
other than DREs (such as GREs) is avoided and optimal
selectivity for AhR interacting molecules is obtained. Typical
TCDD dose–response curves for both CALUX cell lines are
shown in Figure 1B, with EC50 values of 11 and 44pM for
H4IIe-pGudLuc and H4IIe-pDREtataLuc, respectively. Al-
though the EC50 values differ around four times between both
CALUX cell lines, the response to TCDD in the lower
picomolar range is more similar for both lines. The gluco-
corticoid response of the H4IIe-pGudLuc cell line is reflected
in Figure 2A where dexamethasone itself (and cortisol, data not
shown) shows a dose–response curve, although not as active as
TCDD (EC50 of 5nM, reaching around 40% of maximal
TCDD activity at 100nM) raising the possibility that dexa-
methasone can transactivate the AhR. However, the activity of
dexamethasone in the DR CALUX reporter gene assay occurs
at physiological GR-activating levels, and can be inhibited by
the GR antagonist Ru486 suggesting the involvement of GR
instead of AhR (Fig. 2A). The response to glucocorticoids
might be due to GRE-like sequences within the pGudLuc
reporter construct. Using the H4IIe-pDREtataLuc cell line,
containing a minimal reporter construct, the response to dexa-
methasone (and cortisol, data not shown) was decreased
substantially (Fig. 2B). Interestingly, besides the activity of
dexamethasone itself on the pGudLuc reporter construct,
dexamethasone also had an enhanced effect on the dioxin
response in both types of DR CALUX reporter gene cell lines
and this effect could almost completely be inhibited by Ru486
FIG. 1. Schematic representation of dioxin reporter constructs present in DR CALUX reporter cell lines their response to TCDD. (A) The pGudLuc 1.1
construct contains a 484-bp fragment from the upstream region of the mouse CYP1A1 gene, including four DREs, within the MMTV-LTR inserted in the MCS of
the luciferase vector pGL2. The pDREtataLuc construct contains four multimerized rat DREs upstream of a minimal adenovirus E1B TATA promoter inserted in
the MCS of the luciferase vector pGL3. (B) H4IIe-pGudLuc cells (open circle) and H4IIe-pDREtataLuc cells (closed square) were plated in 96-well plates with
phenol red-free DF medium supplemented with 5% DCC-FCS. The next day cells were incubated with TCDD for 24 h. Transcriptional activity is represented as
percentage of maximal induction by TCDD. Each data point is the average of at least three independent experiments ± SEM.
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(Figs. 2C and 2D). The effect of dexamethasone on the dioxin
response observed in H4IIe cells with DR CALUX reporter
gene assays suggests the involvement of GR although via
a mechanism independent of the reporter construct used.
Species-Specific Enhancement of Dioxin Signaling
by Glucocorticoids
To study if the enhancing effects of glucocorticoids on the
dioxin response as determined with DR CALUX reporter cell
lines are a general phenomenon, we performed transient
transfection experiments with a dioxin reporter construct in
rat H4IIe cells and mouse Hepa 1c1c7 cells (Fig. 3). In H4IIe
cells, TCDD could induce the dioxin reporter construct
pGudLuc in a dose-dependent fashion (fourfold induction at
10pM TCDD and 12-fold induction at 1nM TCDD), while
cotreatment with 10nM dexamethasone resulted in highly
increased induction levels (63-fold induction at 10pM TCDD
and 84-fold induction at 1nM TCDD; Fig. 3A, left panel),
comparable with earlier CALUX results. Again, dexametha-
sone itself (10nM) could also induce the pGudLuc reporter
construct (eightfold). Cotransfection of human GR (Fig. 3A:
right panel) as well as rat GR (data not shown) even resulted in
enhanced dexamethasone effects, again showing the
involvement of GR in this response. The interference was not
mutual, as TCDD did not influence glucocorticoid-induced
promoter activity on a pMMTVluc reporter construct (data not
shown). Similar results were obtained with mouse Hepa 1c1c7
cells, which contain a functional dioxin signaling pathway
(Miller et al., 1983) (Fig. 3B). In all these experiments with
H4IIe cells and Hepa 1c1c7 cells, the enhanced glucocorticoid
effects on the dioxin response could also be inhibited by Ru486
(data not shown), suggesting that GR is responsible for these
effects. To test if the observed effects in rodent cell lines can be
extended to human cells, we also tested a panel of human cell
lines for the effect of dexamethasone on the dioxin response.
Human HepG2 cells (Fig. 3C) and T47D cells (Fig. 3D)
showed a dose-dependent response to TCDD, although they
were not as sensitive as the rodent cell lines (reviewed by
Harper et al., 2006), and showed hardly induction with 10pM
TCDD. Surprisingly, cotreatment with dexamethasone (10nM)
did not result in an enhanced TCDD response, although all
human cell lines tested contain functional dioxin (Figs. 3A–D)
and glucocorticoid signaling pathways (Figs. 4A–D). Cotrans-
fection with human or rat GR also did not result in the dexa-
methasone effects observed with H4IIe cells and Hepa 1c1c7
cells, showing that GR was not limiting in these human cell
lines and the property to enhance dioxin signaling was not
depending on the presence of a rodent GR (Figs. 3C and 3D,
FIG. 2. Dexamethasone enhances the TCDD response in stable DR CALUX reporter cell lines. H4IIe-pGudLuc cells (A and C) and H4IIe-pDREtataLuc cells
(B and D) were plated in 96-well plates with phenol red-free DF medium supplemented with 5% DCC-FCS. The next day cells were incubated with TCDD (closed
triangle), dex (closed square), Ru486 (closed inverted triangle), dex/Ru486 (1lM) (open circle), TCDD/dex (1lM) (open triangle), TCDD/dex (1lM)/Ru486
(1lM) (closed circle), or TCDD/Ru486 (1lM) (open square) for 24 h. Transcriptional activity is represented as percentage of maximal induction by TCDD. Each
data point is the average of at least three independent experiments ± SEM.
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right panels). As a control for functional glucocorticoid
signaling, we studied the effect of dexamethasone on the GR
reporter construct MMTV-luc. In all four cell types this
reporter construct could be induced by moderate concentrations
of dexamethasone (although with differences in fold induc-
tion), and these inductions could be inhibited by Ru486
indicating GR-mediated effects (Fig. 4).
To confirm the functional significance of the enhanced
reporter gene induction upon cotreatment with glucocorticoids,
induction of endogenous CYP1A1 enzyme activity was
determined. EROD experiments were performed with wildtype
rat H4IIe cells, measuring CYP1A1 enzyme activity (Fig. 5).
A clear dose-dependent response to TCDD (by means of
increased CYP1A1 enzyme activity) was observed for H4IIe
cells (Fig. 5A) comparable with earlier reported results
(Behnisch et al., 2002). Dexamethasone could enhance this
TCDD response as reporter earlier (Lai et al., 2004), which
could be inhibited completely by Ru486 again indicating
involvement of GR (Fig. 5A). Dexamethasone itself was also
able to increase CYP1A1 enzyme activity (10% of maximal
activity reached by TCDD). Comparable results were obtained
with mouse Hepa 1c1c7 cells (Fig. 5B), with the exceptions
that higher CYP1A1 activities with combined TCDD/dexa-
methasone treatments were reached (up to 300% compared to
150% for H4IIe cells), and that this enhanced response could
not be inhibited completely by Ru486 treatment. Furthermore,
dexamethasone itself was not able to increase CYP1A1 enzyme
activity (Fig. 5B). In the human HepG2 cells (Fig. 5C) and
human T47D cells (Fig. 5D), dexamethasone could not
enhance the TCDD-induced CYP1A1 enzyme activity, con-
firming earlier results obtained with transient transfection
experiments (Fig. 3). Again, both human cell types showed
a 10 times decreased response to TCDD compared to the
rodent cell lines. This decreased response was also observed in
the transient transfection experiments (Fig. 3). In summary,
these EROD experiments confirmed the enhancing effects of
glucocorticoids on TCDD signaling in rodent cells but not in
human cells. The results obtained with the EROD bioassay are
comparable with the results obtained with stable DR CALUX
cell lines and transient transfection experiments.
Enhancement of TCDD-Induced AhR Target Genes by
Dexamethasone in Rat Cells, but not in Human Cells
To study the mechanism of glucocorticoid/dioxin interaction
in H4IIe cells in more detail, the effects of dexamethasone on
the dioxin-response were studied by quantitative reverse
FIG. 3. Dexamethasone enhances the TCDD response of a dioxin reporter construct in rat and mouse cells but not in human cells. H4IIe cells (A), Hepa1
1c1c7 cells (B), HepG2 cells (C), and T47D cells (D) were transiently transfected with pGudLuc 1.1 reporter construct alone (left) or pGudLuc 1.1 and human GR
(right), and treated with TCDD (open bars) or TCDD in combination with dex (10nM) (black bars) for 24 h. Fold induction indicates reporter activity in cells
treated over solvent treated cells. Each bar represents the mean of three independent experiments ± SEM.
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transcription–PCR (RT-PCR) analysis on endogenous AhR
target genes. In addition, to test if the observed effects in the rat
H4IIe cell line can be extended to human, we also tested
a panel of human cell lines (HepG2 cells and T47D cells) for
the effect of dexamethasone on the dioxin response. The genes
tested were well known AhR regulated genes (CYP1A1,
CYP1A2, CYP1B1, GST1A, NMOR; Table 1), but also the
HFH1 gene, identified as a high TCDD-responding gene in
a DNA array experiment using TCDD exposed H4IIe cells
(data not shown) (Table 2). Figure 6 shows an example of the
regulation of CYP1A1 by TCDD in all three cell lines. A clear
dose-dependent induction of the CYP1A1 gene by TCDD is
observed in H4IIe cells (Fig. 6A), even at concentrations as low
as 1pM (Table 2). Dexamethasone could strongly enhance the
CYP1A1 induction by TCDD in these cells (from 1.4 thousand
times induction with 0.1nM TCDD alone up to 5.3 thousand
times induction with a combination of 0.1nM TCDD and 10nM
dexamethasone; Table 2), even without TCDD (four times
induction over solvent control; Table 2). These effects were
mediated by GR, since antagonizing GR with Ru486 (1lM)
resulted in decreased CYP1A1 expression resembling expres-
sion levels as for TCDD alone (Fig. 6A). Besides CYP1A1,
these effects in H4IIe cells were also observed for CYP1A2,
CYP1B1, GST1Ya, NMOR, and HFH1 (Table 2). Interest-
ingly, these effects were not observed in dioxin-responsive
human HepG2 cells (Fig. 6B) and human T47D cells (Fig. 6C)
although the tested genes responded to TCDD alone (except for
GST1A and HFH1). These results indicate that dexamethasone
increases TCDD-induction of endogenous AhR target genes
via a GR-dependent mechanism in rat cells, but not in human
cells. As a control for functional GR, we tested the regulation
of the GR target genes serum/glucocorticoid regulated kinase
(SGK) and FK506 binding protein 51 (rat FKBP5 and human
FKBP51) in H4IIe cells, HepG2 cells, and T47D cells. In H4IIe
cells and T47D cells, the SGK gene was inducible by
dexamethasone in a dose-dependent fashion (Figs. 6A and
6C, right panels), while TCDD had no effect on GSK
expression (not by itself, nor in addition to dexamethasone;
Table 2). The GR antagonist Ru486 could completely block the
dexamethasone-induced expression of SGK, indicating the
involvement of GR. In HepG2 this gene was not induced by
dexamethasone (Fig. 6B and Table 2) although RNA tran-
scripts were present (data not shown). The FKBP51 gene was
induced by dexamethasone in both HepG2 cells and T47D
cells, which could be blocked by Ru486 cotreatment (Table 2).
This gene was not inducible by dexamethasone in rat H4IIe
cells (Table 2). These data show that in all cell lines tested
functional GR signaling is present and that the absence
FIG. 4. Functional GR signaling in rat, mouse, and human cells. H4IIe cells (A), Hepa1 1c1c7 cells (B), HepG2 cells (C), and T47D cells (D) were transiently
transfected with pMMTVluc reporter construct and hGR expression construct and treated with dexamethasone (open bars) or dexamethasone in combination with
Ru486 (1lM) (black bars) for 24 h. Fold induction indicates reporter activity in cells treated over solvent treated cells. Each bar represents the mean of three
independent experiments ± SEM.
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potentiating effect of dexamethasone on the dioxin response in
the human cell lines is not due to absent GR.
Mechanism of Glucocorticoid Enhancement of TCDD
Signaling: Upregulation of AhR in Rat Cells but
not in Human Cells
Since the rat CYP1A1 promoter contains GREs in the first
intron (Linder et al., 1999; Xiao et al., 1995), this might
explain the enhancing effect of dexamethasone on this TCDD
target gene. However, since dexamethasone enhanced the
expression of all tested TCDD target genes in H4IIe cells but
not in human cells (Table 2), GRE dependency seems
questionable. Upregulation of a master gene upstream all these
TCDD target genes seem more likely. One candidate gene
might be AhR itself. To test this hypothesis, we studied the
expression of AhR in rat H4IIe cells by quantitative RT-PCR
(Fig. 7). Expression of this gene was induced by TCDD
(threefold), while dexamethasone enhanced this TCDD-in-
duced expression up to 19-fold. Note that dexamethasone itself
was also able to induce AhR (threefold; Fig. 7A and Table 2).
This TCDD-induced expression of AhR by dexamethasone
was GR dependent, since Ru486 could inhibit this enhance-
ment. The human AhR was not upregulated by TCDD and
TCDD/dexamethasone treatments in HepG2 cells (Fig. 7B) and
T47D cells (Fig. 7C), explaining the observed differences
between the rat cells and the human cells obtained within all
previous assays.
A recent study (Lai et al., 2004) reported that the enhancing
effects of dexamethasone on TCDD-induced CYP1A1 expres-
sion in rat H4IIe cells depend on a posttranscriptional process
(requirement of protein synthesis), although the observed
effects were not very clear. We used stable H4IIe-pGudLuc
cells to study not only the effects of protein synthesis inhibition
by cycloheximide on endogenous CYP1A1 and AhR expres-
sion, but also on the exogenous luciferase gene. For this reason
an early time point of exposure was required. Figure 8A (left
panel) shows that even at 6 h exposure, a clear dose-dependent
induction of the CYP1A1 gene by TCDD is observed in H4IIe-
pGudLuc cells, even at concentrations as low as 1pM (fourfold
induction) as observed for wildtype H4IIe cells at 24 h of
treatment (Table 2). Also at 6-h exposure, dexamethasone
could enhance the CYP1A1 induction by TCDD in these cells:
from 2.8 thousand times induction with 0.1nM TCDD alone up
FIG. 5. Dexamethasone enhances the TCDD-induced EROD response in rat and mouse cells but not in human cells. H4IIe cells (A), Hepa1 1c1c7 cells (B),
HepG2 cells (C), and T47D cells (D) were plated in 96-well plates with phenol red-free DF medium supplemented with 5% DCC-FCS. The next day cells were
incubated with TCDD (closed square), TCDD and dex (10nM) (closed inverted triangle), TCDD and dex (10nM) and Ru486 (1lM) (open square), and dex (closed
triangle) for 24 h. EROD activity is represented as percentage of maximal EROD activity by TCDD. Each data point is the average of at least three independent
experiments ± SEM.
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to 4.8 thousand times induction with a combination of 0.1nM
TCDD and 10nM dexamethasone. These effects were mediated
by GR, since antagonizing GR with Ru486 (1lM) resulted in
decreased CYP1A1 expression resembling expression levels as
for TCDD alone (data not shown). Similar results were obtained
for the exogenous luciferase gene which is under control of a 484-
bp fragment from the upstream region of the mouse CYP1A1
gene, including four DREs, although levels of induction were not
as high as for the endogenous rat CYP1A1 gene (Fig. 8B; left
panel). Cotreatment with cycloheximide resulted in over 10-fold
higher induction levels of CYP1A1 and luciferase genes due to
mRNA accumulation, as observed earlier for CYP1A1 (Lai et al.,
2004). Furthermore, the enhanced TCDD-induced expression of
both CYP1A1 and luciferase by dexamethasone was not observed
after cycloheximide treatment (Figs. 8A and 8B; right panels),
indicating that preceding protein synthesis (such as AhR protein
synthesis) is essential for the enhancing effects of dexamethasone
on TCDD-induced gene induction. After 6 h of exposure, AhR is
TABLE 2
Expression of AhR Target Genes
Cells H4IIe HepG2 T47D
Genea
[TCDD]
(log M) TCDD TCDD/dex
TCDD/dex/
Ru486 TCDD TCDD/dex
TCDD/dex
Ru486 TCDD TCDD/dex
TCDD/dex/
Ru486
Cyp1A1 0 1 ± 0.4 4 ± 1 11 ± 0.4 1 ± 0.5 1 ± 0.0 3 ± 0.2 2 ± 0.9 1 ± 0.0 4 ± 0.6
12 10 ± 2 46 ± 8 74 ± 57 1 ± 0.7 1 ± 0.2 2 ± 0.8 2 ± 0.7 3 ± 0.6 5 ± 1
10 1354 ± 443 5254 ± 309 2250 ± 1280 262 ± 25 229 ± 13 226 ± 11 997 ± 88 1060 ± 171 1000 ± 88
8 2301 ± 220 6469 ± 444 1824 ± 451 931 ± 23 722 ± 85 724 ± 60 3401 ± 217 2674 ± 301 2500 ± 342
Cyp1A2 0 1 ± 0.4 3 ± 1 5 ± 3 1 ± 0.5 0.3 ± 0.1 7 ± 0.5 2 ± 1 1 ± 0.4 2 ± 0.1
12 9 ± 1 27 ± 2 24 ± 5 3 ± 1 1 ± 0.2 1 ± 0.2 2 ± 0.3 1 ± 0.2 2 ± 0.2
10 614 ± 6 1416 ± 83 782 ± 42 5 ± 1 6 ± 0.4 4 ± 1 418 ± 20 123 ± 17 374 ± 49
8 760 ± 19 1652 ± 40 687 ± 47 16 ± 1 8 ± 0.0 3 ± 0.6 1743 ± 431 603 ± 123 1045 ± 113
Cyp1B1 0 1 ± 0.5 2 ± 0.6 1 ± 0.0 1 ± 0.4 1 ± 0.1 3 ± 0.6 1 ± 0.2 1 ± 0.1 1 ± 0.1
12 2 ± 0.5 11 ± 0.4 2 ± 1 2 ± 0.2 1 ± 0.0 1 ± 0.0 1 ± 0.0 1 ± 0.0 1 ± 0.2
10 167 ± 7 898 ± 26 250 ± 50 4 ± 2 4 ± 0.1 3 ± 1 10 ± 0.5 7 ± 2 8 ± 0.1
8 274 ± 72 1161 ± 23 235 ± 49 34 ± 2 30 ± 1 20 ± 0.3 13 ± 1 11 ± 2 10 ± 2
Ahr 0 1 ± 0.4 3 ± 0.7 2 ± 0.5 1 ± 0.2 1 ± 0.2 1 ± 0.2 1 ± 0.1 0.9 ± 0.1 0.8 ± 0.1
12 1 ± 0.2 4 ± 0.6 2 ± 0.1 0.8 ± 0.0 1 ± 0.1 1 ± 0.0 0.9 ± 0.1 1 ± 0.1 0.7 ± 0.1
10 3 ± 0.4 14 ± 0.2 4 ± 0.2 0.9 ± 0.0 1 ± 0.2 1 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 1 ± 0.2
8 3 ± 0.7 19 ± 3 4 ± 0.1 0.5 ± 0.2 0.4 ± 0.1 0.4 ± 0.0 0.8 ± 0.1 0.9 ± 0.0 0.8 ± 0.3
GstYa/GstA1 0 1 ± 0.2 0.7 ± 0.1 1 ± 0.3 1 ± 0.2 0.6 ± 0.4 1 ± 0.1 1 ± 0.6 0.3 ± 0.1 1 ± 0.4
12 1 ± 0.2 0.8 ± 0.2 2 ± 0.3 0.7 ± 0.1 2 ± 0.4 0.8 ± 0.1 0.8 ± 0.3 0.5 ± 0.3 0.8 ± 0.3
10 9 ± 0.3 30 ± 3 13 ± 2 1 ± 0.1 0.9 ± 0.1 0.9 ± 0.0 0.9 ± 0.4 0.8 ± 0.5 0.9 ± 0.2
8 11 ± 0.2 44 ± 2 25 ± 6 0.6 ± 0.2 0.7 ± 0.1 0.4 ± 0.0 0.8 ± 0.5 0.5 ± 0.6 0.2 ± 0.1
Hfh1 0 1 ± 0.2 2 ± 0.2 1 ± 0.1 1 ± 0.3 1 ± 0.1 1 ± 0.2 npb np np
12 1 ± 0.2 2 ± 0.2 1 ± 0.0 1 ± 0.1 1 ± 0.1 1 ± 0.1 np np np
10 12 ± 1 34 ± 4 8 ± 0.4 1 ± 0.0 1 ± 0.1 1 ± 0.1 np np np
8 16 ± 2 70 ± 7 6 ± 1 2 ± 0.2 0.3 ± 0.1 0.2 ± 0.1 np np np
Nmor 0 1 ± 0.2 1 ± 0.2 2 ± 0.7 1 ± 0.2 1 ± 0.1 1 ± 0.1 1 ± 0.2 1 ± 0.1 1 ± 0.2
12 1 ± 0.3 3 ± 1 2 ± 0.4 1 ± 0.0 1 ± 0.1 1 ± 0.2 1 ± 0.2 1 ± 0.3 1 ± 0.1
10 9 ± 0.5 23 ± 4 8 ± 2 2 ± 0.2 2 ± 0.1 2 ± 0.1 3 ± 0.3 1 ± 0.1 2 ± 0.3
8 11 ± 2 29 ± 0.4 6 ± 3 6 ± 0.1 5 ± 0.3 5 ± 0.6 3 ± 0.1 2 ± 0.0 2 ± 0.4
Sgk 0 1 ± 0.2 7 ± 1 2 ± 0.1 1 ± 0.5 0.5 ± 0.1 1 ± 0.1 1 ± 0.5 100 ± 19 2 ± 1
12 0.8 ± 0.3 9 ± 1 2 ± 0.1 1 ± 0.8 ndc nd 2 ± 0.3 nd nd
10 1 ± 0.1 10 ± 2 2 ± 0.4 0.7 ± 0.2 nd nd 1 ± 0.2 nd nd
8 1 ± 0.2 8 ± 1 2 ± 0.2 0.3 ± 0 nd nd 1 ± 0.2 nd nd
Fkbp5/Fkbp51 0 1 ± 0.1 1 ± 0.2 1 ± 0.3 1 ± 0.1 3 ± 0.3 2 ± 0 1 ± 0.1 4 ± 0.5 1 ± 0.1
12 1 ± 0.1 1 ± 0.1 1 ± 0.1 1 ± 0.1 3 ± 0.8 1 ± 0.1 1 ± 0.1 4 ± 0.4 0.9 ± 0.1
10 1 ± 0.1 1 ± 0.2 0.8 ± 0.1 0.9 ± 0.1 3 ± 0.1 1 ± 0.1 1 ± 0 4 ± 0.6 0.9 ± 0.1
8 0.7 ± 0.1 0.9 ± 0.1 0.9 ± 0.2 0.8 ± 0.1 3 ± 0 1 ± 0.2 1 ± 0 5 ± 0.7 0.9 ± 0.1
Notes. H4IIe cells, HepG2 cells, and T47D cells were treated with increasing concentrations of TCDD, TCDD in combination with dexamethasone (10nM)
or TCDD in combination with dexamethasone (10nM) and Ru486 (1lM). Total RNA was isolated after 24 h and cDNA was prepared by reversed transcription.
Gene-specific expression levels were determined by real-time quantitative PCR, and expression of the acidic ribosomal phosphoprotein P0 (36B4) was used for
normalization. Each data point is the average of at least three independent experiments ± SEM.
aFor gene abbreviations see Table 1.
bnp, transcript not present.
cnd, not determined.
REGULATION OF RAT AhR TARGET GENES BY GLUCOCORTICOIDS 463
 by guest on April 4, 2011
toxsci.oxfordjournals.org
D
ow
nloaded from
 
induced twofold by both TCDD and dexamethasone individu-
ally (Fig. 8C; left panel). Combined exposure of TCDD and
dexamethasone did not enhance the expression of AhR after 6 h,
in contrast to 24 h of exposure (see Fig. 7A). Cotreatment with
cycloheximide did not result in reduction of the enhanced effect
of dexamethasone as observed for TCDD-induced CYP1A1 and
luciferase (Fig. 8C; right panel); it even resulted in enhanced
AhR induction. This enhancement could be blocked completely
by Ru486, suggesting the involvement of GR (data not shown).
These results indicate that synthesis of a protein such as AhR is
essential for the dexamethasone-mediated enhancement of
TCDD-induced genes.
FIG. 6. Dexamethasone enhances the expression of the dioxin target gene CYP1A1 in rat cells but not in human cells. H4IIe cells (A), HepG2 cells (B), and
T47D cells (C) were treated with increasing concentrations of TCDD (open bars, left panels), TCDD in combination with dexamethasone (10nM) (black bars, left
panels), TCDD in combination with dexamethasone (10nM) and Ru486 (1lM) (hatched bars, left panels), or increasing concentrations of dexamethasone (black
bars, right panels). Total RNA was isolated after 24 h and cDNA was prepared by reversed transcription. Induction of CYP1A1 (left panels) and SGK (right panels)
mRNA was determined by real-time quantitative PCR. Expression of the acidic ribosomal phosphoprotein P0 (36B4) was used for normalization. Each data point
is the average of at least three independent experiments ± SEM.
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To explain the differences in AhR expression between rat
H4IIe cells and human HepG2 cells and T47D cells, we analyzed
the promoter region of this gene. Two GRE-like sequences were
identified that meet the criterion of being highly conserved
between mouse and rat, but not human (Fig. 9A). The GRE
starting at position 2317 has a consensus 3# half site, while the
more upstream high affinity site starting at position 7223
deviates at positions 4 and 6 from the canonical sequence [a/
t]GT[c/t]CT (Nelson et al., 1999). Both sites were completely
conserved between rat and mouse, except for a single C-T
difference in the 5# half site of the more downstream GRE.
Furthermore, two putative XREs meeting the criterion of the
consensus XRE [g/t][c/t]GCGTG[c/a/t] (Swanson et al., 1995) at
positions 339 and 303 within the rat Ahr promoter were iden-
tified, which are also conserved between rat and mouse, but absent
in the human Ahr gene (Fig. 9B). The presence of such XREs
within the rat Ahr gene could not only explain the induction of
AhR by TCDD itself (Fig. 7A and Table 2), but also the co-
operative effect of ligated AhR and GR in the induction of rat AhR.
DISCUSSION
The results described in the present study clearly show that
glucocorticoids enhance AhR signaling in rodent cells. These
data are in accordance with previously reported studies show-
ing the enhanced effects of glucocorticoids on TCDD signaling
in rodents (Abott, 1995; Lai et al., 2004; Linder et al., 1999;
Monostory et al., 2005). While the observed effects of
glucocorticoids on dioxin signal transduction are mediated by
GR in rodent cells (rat H4IIe cells and mouse Hepa1 1c1c7
cells), this is not the case in the human cells studied (HepG2
and T47D cells), although AhR and GR signaling pathways are
both present and active in these human cell lines. Also in other
human cell lines, no enhanced effects of glucocorticoids on
AhR signaling have been observed (Monostory et al., 2005).
For all the studied endogenous AhR target genes (CYP1A1,
CYP1A2, CYP1B1, GSTYa/GST-A1, HFH1, and NMOR),
TCDD-induced mRNA expression is enhanced by dexameth-
asone in rat H4IIe cells, but not in human HepG2 cells and
T47D cells. This enhancement of AhR target gene expression
by glucocorticoids was reported earlier for CYP1A1 (Lai et al.,
2004; Mathis et al., 1989; Sherratt et al., 1990; Pinaire et al.,
2004; Xiao et al., 1995), GST (Xiao et al., 1995; Sherratt et al.,
1990) and UGT (Xiao et al., 1995) in various types of rat cells,
although the last study also reported negative regulation of
glucocorticoids on the AhR target genes QOR and ALDH3C in
rat hepatocytes (Xiao et al., 1995). It was proposed earlier that
a functional GRE present in the first intron of CYP1A1 is
responsible for the modulating expression of AhR target genes
by glucocorticoids (Linder et al., 1999). In our study we do not
find these effects in human cell lines. Furthermore, complex
(pGudLuc) and minimal promoter (pDREtataLuc) reporter
constructs show that the enhancing effects of glucocorticoids
FIG. 7. Dexamethasone enhances the TCDD-induced expression of AhR
in rat cells but not in human cells. H4IIe cells (A), HepG2 cells (B), and T47D
cells (C) were treated with increasing concentrations of TCDD (open bars),
TCDD in combination with dexamethasone (10nM) (black bars), or TCDD in
combination with dexamethasone (10nM) and Ru486 (1lM) (hatched bars).
Total RNA was isolated after 24 h and cDNA was prepared by reversed
transcription. Induction of AhR mRNA was determined by real-time
quantitative PCR. Expression of the acidic ribosomal phosphoprotein P0
(36B4) was used for normalization. Each data point is the average of at least
three independent experiments ± SEM.
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still can occur, even in the absence of the GRE in the CYP1A1
gene. In addition, as suggested earlier, it seems not likely that
all these glucocorticoid regulated AhR target genes contain
additional GREs in their promoters explaining these enhancing
effects of dexamethasone, further strengthened by the fact that
only the studied rat genes show this phenomenon. Therefore,
the observed effects of glucocorticoids in dioxin signal
transduction seem to be mediated by GR via direct induction
of AhR in rat H4IIe cells, but not in human HepG2 and T47D
cells. This is reflected by a 19 times induction of AhR mRNA
when H4IIe cells are exposed to TCDD and dexamethasone,
while TCDD or dexamethasone exposure alone resulted in
three times and four times induction, respectively. These
effects were not observed in the human cells studied. Further-
more, the observed dexamethasone-mediated enhancement of
dioxin target gene induction was clearly shown to depend on
a posttranscriptional process, likely AhR protein synthesis.
This was shown earlier for CYP1A1 in H4IIe cells (Lai et al.,
2004), but their results were not clear due to the early time
point of exposure (no enhanced dexamethasone effect after
5 h), or super induction effects due to cycloheximide after 24 h
of exposure. In our study, enhanced effects of dexamethasone
on TCDD-induced CYP1A1 and luciferase expression were
observed after 6 h which could blocked by Ru486 indicating
the involvement of GR. The protein synthesis inhibitor
cycloheximide could reduce the enhanced expression levels
of CYP1A1 and luciferase to the levels of TCDD treatment
alone, suggesting that the enhancing effect of dexamethasone
via GR on TCDD target genes requires the synthesis of an
additional protein such as AhR, which contains two GREs in
its promoter region. Although both rat H4IIe cells and mouse
Hepa1 1c1c7 cells show enhanced AhR signaling by gluco-
corticoids, this effect might be cell type specific. Although the
experimental conditions were different, Brake et al. (1998)
showed that AhR and CYP1B1 protein levels were reduced
with a factor two after combined TCDD and dexamethasone
exposure in rat mammary fibroblasts showing differences
between fibroblasts and liver cell lines.
Higher AhR levels seem responsible for the enhanced
induction of TCDD target genes in H4IIe cells. AhR levels can
be limiting in cells and it has been demonstrated that over-
expression of AhR in human neuro-2A cells and human
H295R cells increased activities of AhR target genes Sim1 and
StAR on reporter constructs, respectively (Sugawara et al.,
2001; Yang et al., 2004). The GR-mediated upregulation of
AhR is probably due to the presence of GREs in the rat AhR
promoter but not in the human AhR promoter (this study).
Murine AhR promoter analysis revealed a GC-rich, TATA-less
promoter containing five putative Sp1-like binding sites
(Garrison and Denison, 2000), well conserved in the human
AhR promoter (Eguchi et al., 1994). In addition, a putative
XRE was reported for the murine AhR promoter (Garrison and
Denison, 2000). In our study, two GRE-like sequences were
found that were specific for the rodent Ahr genes. Recently, it
FIG. 8. Effect of cycloheximide on dioxin-induced CYP1A1, AhR, and
luciferase expression in rat H4IIe-pGudLuc cells. H4IIe-pGudLuc cells were
treated with increasing concentrations of TCDD (open bars) and TCDD in
combination with dexamethasone (10nM) (black bars) (left panel) or the same
treatments in combination with 10 lg cycloheximide (CHX; right panel). Total
RNA was isolated after 6 h and cDNA was prepared by reversed transcription.
Induction of rCYP1A1 (A), luciferase (B), and rAhR (C) mRNA was
determined by real-time quantitative PCR. Expression of the acidic ribosomal
phosphoprotein P0 (36B4) was used for normalization. Each data point is the
average of at least three independent experiments ± SEM.
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was reported that functional GREs tend to be very highly
conserved between species (Almon et al., 2005) and the
present pair of sequences for rat and mouse qualifies as such,
while the corresponding human sequence does not. Further-
more, two XRE-like sequences within the Ahr gene were found
to be fully conserved between rat and mouse, but not in the
human Ahr promoter at these positions, although here a putative
XRE was found at position 7393 (data not shown). These
XREs within the rat Ahr gene seem necessary for the induction
of AhR by TCDD, and may also be involved in the cooperative
effect of TCDD and glucocorticoids in the induction of rat
AhR. Factual proof of functionality of both identified GREs
and XREs should come from testing of Ahr induction in
a relevant target cell or organ, characterization of the sequences
in reporter gene assays, and/or chromatin immunoprecipitation.
It is striking that both AhR and one of its important target
genes CYP1A1 carry both GREs in their promoter and are
synergistically regulated by xenobiotics and glucocorticoids.
Apparently, at least in rodents, the activation of the endogenous
stress system of the whole organism acts in synergy with the
cellular defense response in counteracting toxicity through
multiple genetic targets.
From a practical point of view, the interactions of signal
transduction pathways by dioxins and glucocorticoids could have
consequences for quantitative dioxin analysis using the DR
CALUX bioassay. Complex samples such as human serum
samples, may contain a combination of both dioxin receptor
agonists (such as TCDD, PAHs, and PCBs) and glucocorticoids
(cortisol and prescription glucocorticoids such as dexa-
methasone) which would then overestimate the concentration
of dioxins. An example of this possibility is the direct serum
exposure or simple serum extract exposure to DR CALUX cells
resulting in very high TCDD toxic equivalents (TEQs) compared
to high-resolution gas chromatography–mass spectrometry
TEQs (Ziccardi et al., 2000 and data not shown). In our
laboratory, glucocorticoids were shown to be efficiently removed
from matrices via clean-up procedures in the dioxin sample work-
up in standard dioxin analysis with the DR CALUX bioassay (as
examined using the GR CALUX bioassay (Sonneveld et al.,
2005) measuring glucocorticoidal activity; data not shown).
In our study, insight has been gained into the interactions of
signal transduction pathways by dioxins and glucocorticoids
which provide explanations for known interactions between
stress-related pathways and dioxin effects. The immunotoxic
effects of TCDD, notably atrophy of the thymus and
suppression of thymus-dependent immunity, are mediated by
the AhR, expressed in the epithelial cells of the thymus
(reviewed by Vos et al., 1998). The sensitivity of humans to
the immunotoxic effects of TCDD, both in vitro and in vivo, is
still controversial as contradictory data have been reported
while for rodents clear TCDD-induced thymic atrophy (in vitro
as well as in vivo) is described (Poland and Glover, 1980).
Extrapolation of data from animal studies to man poses
difficulties as the interspecies difference in sensitivity to TCDD
is high. In other words, evaluation of the risks posed by dioxins
to humans is hampered by the exceptionally large inter- and
intraspecies differences occurring in laboratory animals for
some of their effects. These differences culminate in acute
lethality: for the most toxic dioxin TCDD, the hamster is about
1000-fold more resistant than the guinea pig and a difference of
the same magnitude exists between a TCDD-sensitive rat
strain, Long–Evans and a TCDD-resistant strain, Han/Wistar.
The same dramatic differences in TCDD sensitivity within
species exist for mice (Poland et al., 1994) and birds (Karchner
FIG. 9. Positional conserved putative GREs and XREs in rat, mouse, and human AhR genomic sequences. Orthologous rat, mouse, and human Ahr genomic
sequences were extracted from the ensembl database and aligned. Two positionally conserved GREs in rat and mouse Ahr genes were identified at 7233
and 2328, respectively, and shaded in gray (7233) or black (2328) (A). Two conserved XREs were identified at 339 and 303 in rat and mouse Ahr genes,
respectively, and shaded in black (B).
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et al., 2006). Besides these clear toxicity differences between
rodents, also species differences between TCDD affinity for the
AhR exist. In our study we found a decreased affinity of TCDD
for the human AhR compared to rat and mouse AhR as
reviewed earlier by Harper et al. (2006). Reporter gene assays
showed that a dioxin reporter construct already could be
induced at low TCDD levels in rat H4IIe cells and mouse
Hepa1 1c1c7 cells but not in human HepG2 and T47D cells. In
addition, EROD experiments showed picomolar range EC50
values for TCDD in H4IIe cells and Hepa1 1c1c7 cells, while
human cells were 50–100 times less sensitive to TCDD. These
differences in sensitivity to TCDD are believed to be caused by
differences in the ligand-binding affinity of polymorphic AhR
variants within and across species. In contrast, susceptibilities
to the adverse effects of TCDD are not always necessarily
attributable to polymorphism of the AhR gene: two rat strains
with identical AhR structure showed a large difference in
susceptibility (Kawakami et al., 2006), suggesting that the
sequence of the AhR itself seems not always responsible for
observed differences in terms of TCDD toxicity and therefore
other mechanisms are likely involved. GR-mediated effects
might be one of these mechanisms involved in differences in
TCDD toxicity albeit both GR and AhR should be present in the
target tissues/organs (e.g., liver, thymus) and more importantly,
the TCDD signal should be amplified by GR (e.g., by
upregulation of AhR). For this last proposed prerequisition we
provided evidence (on a cellular level) that this might be specific
for rodents but not for humans. Factual proof should come from
rodent animal studies combining both TCDD and dexametha-
sone exposures, taking both toxicity and AhR target gene
induction in appropriate organs (liver and thymus) as endpoints.
Further evidence for AhR upregulation and consequent elevation
of TCDD target genes comes from a study using human cells,
although by another nuclear hormone receptor. Peroxisome
proliferator activator receptor alpha (PPARalpha) activation
potentiates AhR-induced CYP1A1 expression in human Caco-2
cells via induced AhR expression, although with very high
concentration PPARalpha ligand (Fallone et al., 2005). The
possible GR-mediated effect amplification of dioxin-like com-
pounds (TCDDs, PCBs, PAHs) by induced levels of AhR in
rodents suggests a higher sensitivity for rodents than for humans,
especially when increased stress conditions (resulting in elevated
cortisol levels) are present. Furthermore, these data consequently
suggest the possibility that dioxin responses in rodent-based
models for dioxin toxicity may overestimate the hazard in
comparison to humans and may possibly have implications for
risk assessment.
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